Mumbai, April 21, 2018: Pharma Major.Glenmark Pharmaceuticals on Wednesday said that Glenmark Pharmaceuticals Inc USA has received final approval from the US health regulator for Tacrolimus ointment 0.1 per cent.
The product is a generic version of Protopic ointment, of Leo Pharma AS in the same strength, company said in a filing with BSE.
According to IQVIA sales data for the 12-month period ending February 2018, Protopic ointment 0.1 percent achieved annual sales of around USD 109 million, the filing said.
Tacrolimus ointment 0.1 per cent is used for treating a topic dermatitis (eczema).
The company’s current portfolio consists of 132 products authorised for distribution in the US market and 61 Abbreviated New Drug Applications (ANDA’s) pending approval with the USFDA, the filing added.
United News of India